To clarify Charm's statement about the 5% of patients Erbitux is worthless for, it's due to K-ras gene mutation in the cancerous cells. This is very prevalent in Colorectal Cancers (around 40%) and is the reason patients are gene tested before treatment.

This happens in around 5% to Head & Neck Cancer patients "However" to my knowledge gene testing isn't standard for HNSCC patients to see if they fall within that 5%, but it should be. Where 95% won't be affected by this, it could mean everything for the 5% that fall in this category.

Great response Charm, thank you.